The clinical relevance of dysfunctional HDL in patients with coronary artery disease: A 3-year follow-up study

International Journal of Cardiology

Volumn 158, Issue 1, 2012, Pages 158-160

  Paneni, Francesco ^a   Cosentino, Francesco ^b   Marrara, Federica ^b   Palano, Francesca ^b   Capretti, Giuliana ^b   Gregori, Mario ^b   Tocci, Giuliano ^a   Testa, Marco ^b   Volpe, Massimo ^a,b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cardiovascular outcome; Coronary artery disease; Dysfunctional HDL

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL; URIC ACID;

ANGIOCARDIOGRAPHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LETTER; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; STROKE; TRANSIENT ISCHEMIC ATTACK; URIC ACID BLOOD LEVEL;

EID: 84862015597     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.04.032     Document Type: Article

References (17)

1. Q. Zhang, L. Liu, and X.Y. Zheng Protective roles of HDL, apoA-I and mimetic peptide on endothelial function: through endothelial cells and endothelial progenitor cells Int J Cardiol 133 2009 286 292
2. F. Paneni, F. Palano, and M. Testa Novel lipid targets in the era of metabolic syndrome: toward a better prediction of cardiovascular risk High Blood Press Cardiovasc Prev 16 2009 93 100
3. D.J. Gordon, J.L. Probstfield, and R.J. Garrison High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
4. D.J. Smith Dysfunctional HDL as a diagnostic and therapeutic target Arterioscler Thromb Vasc Biol 30 2010 151 155
5. B.J. Ansell, and A.M. Fogelmann The paradox of dysfunctional HDL Curr Opin Lipidol 18 2007 427 434
6. B.J. Ansell, M. Navab, and S. Hama Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favourably affected by simvastatin treatment Circulation 108 2003 2751 2756
7. C. Besler, K. Heinrich, and L. Rohrer Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease J Clin Invest 121 2011 2693 2708
8. A.R. Tall CETP inhibitors to increase HDL cholesterol levels N Engl J Med 356 2007 1364 1366
9. D. Duffy, and D.J. Rader Update on strategies to increase HDL quantity and function Nat Rev Cardiol 6 2009 455 463
10. K.G. Alberti, R.H. Eckel, and S.M. Grundy International Diabetes Federation Task Force on Epidemiology and Prevention Circulation 120 2009 1640 1645
11. C. Besler, K. Heinrich, M. Riwanto, T.F. Lüscher, and U. Landmesser High-density lipoprotein-mediated anti-atherosclerotic and endothelial- protective effects: a potential novel therapeutic target in cardiovascular disease Curr Pharm Des 16 2010 1480 1493
12. S.A. Sorrentino, C. Besler, and L. Rohrer Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy Circulation 121 2010 110 122
13. S. Dodani, R. Kaur, S. Reddy, G.L. Reed, M. Navab, and V. George Can dysfunctional HDL explain high coronary artery disease risk in South Asians? Int J Cardiol 129 2008 125 132
14. W.E. Boden, J.L. Probstfield, and T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. AIM-HIGH Investigators N Engl J Med 365 2011 2255 2267
15. B.J. Arsenault, P. Barter, and D.A. DeMicco Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers J Am Coll Cardiol 57 2011 63 69
16. P.J. Patel, A.V. Khera, K. Jafri, R.L. Wilensky, and D.J. Rader The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease J Am Coll Cardiol 58 2011 2068 2075
17. A.J. Coats, and L.G. Shewan Ethics in the authorship and publishing of scientific articles Int J Cardio 153 2011 239 240